People News

aTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting

4.0 from 1 vote
Friday, March 22, 2019

Learn more about:

SAN DIEGO - aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced that data from its successful pilot study with the University of Nebraska Medical Center will be presented in an abstract at the 2019 AACR Annual Meeting, which is being held March 29 - April 3 at the Georgia World Conference Center in Atlanta.

Details of the poster presentation are as follows:
Title: 4587/11 - The N-terminal domain of HARS is a novel NRP2 ligand and can regulate NRP2-dependent macrophage function
Presenter: Dr. Kaustubh Datta, Professor of Biochemistry and Molecular Biology at University of Nebraska Medical Center
Session: Session PO.TB06.10 - Immunity in the Microenvironment
Date/Time: April 3, 2019 from 8:00am-12:00pm EDT
Location: Section 4

The poster may be accessed on the aTyr Pharma website at following the presentation.

About ATYR1923
aTyr is developing ATYR1923 as a potential therapeutic for patients with interstitial lung diseases. ATYR1923, a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase (HARS) fused to the FC region of a human antibody, is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states. aTyr initiated a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis in the fourth quarter of 2018. This Phase 1b/2a study is a multiple-ascending dose, placebo-controlled, first-in-patient study of ATYR1923 that has been designed to evaluate the safety, tolerability, steroid sparing effect, immunogenicity and pharmacokinetics (PK) profile of multiple doses of ATYR1923. For the Phase 1b/2a trial, aTyr is collaborating with the Foundation for Sarcoidosis Research (FSR), the nation's leading nonprofit organization dedicated to finding a cure for sarcoidosis and improving care for sarcoidosis patients. Under the terms of the collaboration, FSR will assist with clinical trial site initiation and patient enrolment.

About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr's research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes. aTyr is focused on the therapeutic translation of the Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase gene family. ATYR1923 is a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases and other immune-mediated diseases. For more information, please visit

Joyce Allaire
Managing Director, LifeSci Advisors, LLC

Source: aTyr Pharma
4.0 from 1 vote
Free Newsletter
Trending News
Related Videos
by Abidemi Uruejoma
by Abidemi Uruejoma